BIZARRE: 2 - You Need To See This

A Custom mRNA Therapy Built from Each Patient's Tumor Improved Melanoma Recurrence-Free Survival in a Phase 3 Trial

Merck and Moderna say intismeran autogene plus Keytruda met its primary endpoint in a Phase 3 melanoma trial. What the topline result does and does not show.

Medical Daily · Aug 20

Global Market: China, Hong Kong stocks rebound as healthcare and tech shares rally

China and Hong Kong stocks rebounded on Thursday, led by healthcare and technology shares, after a sharp selloff in the previous session. Fresh share buyback announcements also supported sentiment, while gains in South Korea and Japan helped broader Asian markets recover. Investors remained cautious amid heightened volatility.

The Economic Times · Aug 20

Short Sellers Just Lost $5B on the Wrong Pharma Bet: Cancer Vaccine Sends Stock Soaring 177%

Moderna's shares surged 177% after positive cancer vaccine trial results, causing $5 billion losses for short sellers. This marks a potential shift beyond its COVID-19 vaccine business.

International Business Times UK · Aug 20

Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For

Moderna Inc.’s (NASDAQ:MRNA) latest cancer-vaccine breakthrough could be doing more than sending its stock sharply higher. It may be giving investors a reason to revisit an mRNA investment thesis that has largely been defined by COVID-19. ETFs tied to precision medicine names are also getting a boost.

Benzinga · Aug 19

Moderna Stock Soars More Than 100% on Cancer Vaccine Breakthrough: What Investors Are Betting On

Moderna shares surged after its personalised mRNA cancer treatment met key Phase 3 trial endpoints in melanoma with Merck's Keytruda.

International Business Times UK · Aug 19

Stocks Finish Mixed as Bond Yields Fall and Chipmakers Slide

The S&P 500 Index ($SPX ) (SPY ) closed up by +0.21% on Wednesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.22%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.22%. E-mini S&P futures (ESU26 ) rose +0.20%, and September E-mini...

Barchart · Aug 19

Stocks Snap Losing Streak as Treasury Yields Ease: Stock Market Today

Yields on the 10-year and 30-year Treasuries pulled back Wednesday after the Treasury Department announced new buyback levels.

Kiplinger · Aug 19

Trump Adds to Wealth With Moderna Stock Gains: Here’s How Much President Made

Moderna Inc. (NASDAQ:MRNA) stock soared Wednesday after the company and Merck reported positive Phase 3 results for a personalized mRNA cancer vaccine, marking a major milestone for the emerging technology. Shares jumped more than 100%, reaching levels not seen since May 2024.

Benzinga · Aug 19

US stocks: US market rises as yields ease, Moderna lifts healthcare stocks

US stock markets enjoyed a boost as easing bond yields and a spike in Moderna shares contributed to a favorable trading environment. Despite the Federal Reserve's minutes highlighting inflation concerns and discussions on rate hikes, investors remained optimistic. The Treasury's announcement of liquidity support revitalized riskier assets, particularly in tech…

The Economic Times · Aug 19

'Breakthrough' mRNA cancer drug curbs melanoma in large trial

WASHINGTON (UNITED STATES) - US drugmakers Merck and Moderna said Wednesday a personalized cancer treatment had shown success in reducing the recurrence of melanoma tumors in a late-stage trial hailed by experts as a "breakthrough."

Bangkok Post · Aug 19